Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging

Centre Hospitalier Universitaire, Amiens

Status: Terminated

Conditions: Alzheimer Disease; Mild Cognitive Impairment; Vascular Dementia

Treatments: Other: Magnetic resonance imaging; Other: Positron emission tomography

Study type: Interventional

Funder types: Other

Identifiers

NCT01815112

2007-A01009-44 (Registry Identifier)

PI07-PR-MEYER1

Details and patient eligibility

About

The physio-pathology of Alzheimer's disease (AD) remains unknown and there is no cure. Thus, the search for objective markers of preclinical first signs of cognitive impairment, is currently a major public health issue. Early detection of the disease is a major challenge to hope to slow or even stop the neurodegenerative process before the stage of dementia.

In AD the investigators observe:

• A reduction in the volume of brain hippocampi associated with an alteration of the diffusion of water molecules in the white matter.
• A structural brain degeneration coupled with a decrease in cerebral glucose metabolism.

Recent publications show that cerebrospinal fluid (CSF)flow is also altered, probably due to dysfunction of the choroid plexus. Hence the potential interest to study is, in addition to conventional imaging, the imaging of CSF dynamics and choroid plexus metabolism. In that aim,the investigators use two imaging modalities:

• Magnetic resonance imaging (MRI) is used to assess blood and CSF flow in the brain
• Positron emission tomography (PET) is used to assess glucose metabolism in grey/white matter and also in choroid plexus.

The investigators expect that, because of choroid plexus atrophy in AD, CSF flow would be altered as well as glucose metabolism dynamic in choroid plexus.

Enrollment: 60 patients

Sex: All

Ages: 65+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age: over 65
• Participants (or representatives) gave their written informed consent
• Dementia diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria
• For Alzheimer arm: probable Alzheimer based disease according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association ) criteria
• For vascular dementia: diagnosis based on NINDS-AIREN (National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences) criteria
• For MCI: diagnosis based on Petersen index

Exclusion criteria

• Claustrophobia
• Diabetes
• Cardiovascular disease
• Glycemia over 1.3 g/L
• Lumbar puncture within one week before MRI examination
• Non MR-compatible implant
• Suspected brain metastases
• No informed consent signature

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

60 participants in 5 patient groups

Alzheimer

Experimental group

Description:

Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations.

Treatment:

Other: Positron emission tomography

Other: Magnetic resonance imaging

Vascular dementia

Experimental group

Description:

Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.

Treatment:

Other: Positron emission tomography

Other: Magnetic resonance imaging

Mild cognitive impairment (MCI)

Experimental group

Description:

Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.

Treatment:

Other: Positron emission tomography

Other: Magnetic resonance imaging

Healthy subjects (MRI)

Experimental group

Description:

Healthy subjects agreeing to undergo magnetic resonance imaging examination.

Treatment:

Other: Magnetic resonance imaging

Healthy subjects (PET)

Experimental group

Description:

Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.

Treatment:

Other: Positron emission tomography